Skip to content

Absci Corporation ABSI Investment Proceeds

Investment Proceeds at other companies

Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$107.75M+50.9%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$35M-74.5%
Xencor logo
XencorXNCR
$99.97M-16.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$10M
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$25.51M
Precigen logo
PrecigenPGEN
$55.1M+1,105%

Other financials

Income statement

See full
Revenue$215.0K-81.8%
Operating income-$30.8M-11.2%
Net income-$29.6M-12.3%
EPS (diluted)-$0.19+9.5%

Balance sheet

See full
Cash & equivalents$9.7M-84.9%
Total debt$4.0M-37.2%
Total equity$172.0M-13.5%
Total assets$195.6M-15.9%

Cash flow

See full
Operating cash flow-$26.3M-20.5%
CapEx$30.0K+20.0%
Free cash flow-$26.3M-20.5%

Valuation

See full
Market cap$1.57B+341%
Enterprise value$1.57B+425%
P/S855.5×+782×

Profitability

See full
Operating margin-6,723%-14,525pp
Net margin-6,450.8%-13,699pp
FCF margin-5,365.2%-9,300pp

Returns & leverage

See full
Return on equity-63.9%+28.0pp
Debt / equity0.0×
Current ratio6.6×+0.9×

Where this comes from

Reported directly by Absci Corporation in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities.

The official record: Absci Corporation’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Absci Corporation's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Absci Corporation's investment proceeds?
Absci Corporation (ABSI) reported investment proceeds of $26M in Q1 2026.
How has Absci Corporation's investment proceeds changed year-over-year?
Absci Corporation's investment proceeds increased by 4.0% year-over-year, from $25M to $26M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.